Antitumor actions of ruthenium(III)-based nitric oxide scavengers and nitric oxide synthase inhibitors

Molecular Cancer Therapeutics

Volumn 10, Issue 9, 2011, Pages 1571-1580

  Flitney, Frederick W ^a   Pritchard, Rebecca J ^a   Kennovin, Gordon D ^a   Bisland, Stuart K ^a   Hirst, David G ^b   Fricker, Simon P ^c  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMD 6221; AMD 6245; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOSARCOMA; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ENZYME INHIBITORS; FREE RADICAL SCAVENGERS; MALE; NEOVASCULARIZATION, PATHOLOGIC; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; RATS; RUTHENIUM; SARCOMA, EXPERIMENTAL; TRANSPLANTATION, ISOGENEIC; TUMOR BURDEN;

EID: 80052774776     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0840     Document Type: Article

References (45)

1. Palmer RM, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988;153:1251-6.
2. Forstermann U, Kleinert H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 1995;352:351-64.
3. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298:249-58. (Pubitemid 24072462)
4. Radomski MW, Jenkins DC, Holmes L, Moncada S. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 1991;51:6073-8.
5. Jansson OT, Morcos E, Brundin L, Lundberg JO, Adolfsson J, Soderhall M, et al. The role of nitric oxide in bacillus calmette-guerin mediated anti-tumor effects in human bladder cancer. Br J Cancer 1998;78:588-92.
6. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994;54:1352-4. (Pubitemid 24108080)
7. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998;90:587-96. (Pubitemid 28204802)
8. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995;55:727-30.
9. Fukumura D, Yuan F, Endo M, Jain RK. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol 1997;150:713-25. (Pubitemid 27073798)
10. Doi K, Akaike T, Horie H, Noguchi Y, Fujii S, Beppu T, et al. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 1996;77:1598-604. (Pubitemid 26111840)
11. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990;101:746-52. (Pubitemid 20357206)
12. Griffiths MJ, Messent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993;110:963-8. (Pubitemid 24005226)
13. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993;233:119-25. (Pubitemid 23091752)
14. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJ, et al. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 1997;272:4959-63. (Pubitemid 27090046)
15. Hirst DG, Flitney FW. The physiological importance and therapeutic potential of nitric oxide in the tumor-associated vasculature. In: Bicknell R, Lewis CE, Ferrara N, editors. Tumor angiogenesis. Oxford: Oxford University Press; 1997. p. 154-67.
16. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 1992;107:1092-5.
17. Wood PJ, Stratford IJ, Adams GE, Szabo C, Thiemermann C, Vane JR. Modification of energy metabolismand radiation response of a murine tumor by changes in nitric oxide availability. Biochem Biophys Res Commun 1993;192:505-10. (Pubitemid 23227352)
18. Kennovin GD, Hirst DG, Stratford MRL, Flitney FW. Inducible nitric oxide synthase is expressed in tumor-associated vasculature: inhibition retards tumor growth. In: Moncada S, Feelisch M, Busse R, Higgs EA, editors. The biology of nitric oxide. London: Portland Press; 1994. p. 473-9.
19. Tozer GM, Prise VE, Chaplin DJ. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 1997;57:948-55. (Pubitemid 27098023)
20. Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res 2001;92:439-51. (Pubitemid 32427781)
21. Pipili-Synetos E, Sakkoula E, Maragoudakis ME. Nitric oxide is involved in the regulation of angiogenesis. Br J Pharmacol 1993;108:855-7. (Pubitemid 23102198)
22. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des 2003;9:521-30. (Pubitemid 36221720)
23. Nicotera P, Bonfoco E, Brune B. Mechanisms for nitric oxide-induced cell death: involvement of apoptosis. Adv Neuroimmunol 1995;5:411-20. (Pubitemid 26021247)
24. Hirst DG, Robson T. Nitrosative stress as a mediator of apoptosis: implications for cancer therapy. Curr Pharm Des 2010;16:45-55.
25. Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Radomski MW, Moncada S. Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer 1994;70:847-9. (Pubitemid 24331075)
26. Thomsen LL, Scott JM, Topley P, Knowles RG, Keerie AJ, Frend AJ. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: Studies with 1400W, a novel inhibitor. Cancer Res 1997;57:3300-4. (Pubitemid 27351750)
27. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumor growth and metastasis by stimulating tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2000;86:30-9. (Pubitemid 30133983)
28. Bottomley F. Nitrosyl complexes of ruthenium. Coord Chem Rev 1978;29:7-32.
29. Cameron BR, Darkes MC, Yee H, Olsen M, Fricker SP, Skerlj RT, et al. Ruthenium(III) polyaminocarboxylate complexes: Efficient and effective nitric oxide scavengers. Inorg Chem 2003;42:1868-76.
30. Fricker SP. Metal complexes as therapeutic agents in nitrogen monoxide modulation. In: Sigel A, Sigel H, editors. Metal ions and their complexes in medication; metal ions in biological systems. New York: Marcel Dekker; 2004. p. 421-80.
31. Mosi R, Seguin B, Cameron B, Amankwa L, Darkes MC, Fricker SP. Mechanistic studies on AMD6221: a ruthenium-based nitric oxide scavenger. Biochem Biophys Res Commun 2002;292:519-29. (Pubitemid 34694294)
32. Fricker SP, Slade E, Powell NA, Vaughan OJ, Henderson GR, Murrer BA, et al. Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases. Br J Pharmacol 1997;122:1441-9. (Pubitemid 27503936)
33. Wohl JS, Baggs A, Lin JL, Fink MP, Dhupa N. Use of jugular venous blood, compared with mixed venous blood, for measurement of venous oxygenation indices in a porcine model of endotoxic shock. Am J Vet Res 1997;58:910-4. (Pubitemid 127470802)
34. Pieper GM, Roza AM, Adams MB, Hilton G, Johnson M, Felix CC, et al. A ruthenium (III) polyaminocarboxylate complex, a novel nitric oxide scavenger, enhances graft survival and decreases nitrosylated heme protein in models of acute and delayed cardiac transplant rejection. J Cardiovasc Pharmacol 2002;39:441-8. (Pubitemid 34175069)
35. Tozer GM, Shaffi KM. Modification of tumor blood flow using the hypertensive agent, angiotensin II. Br J Cancer 1993;67:981-8. (Pubitemid 23147489)
36. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, et al. Age-dependent impairment of angiogenesis. Circulation 1999;99:111-20. (Pubitemid 29035965)
37. Cernadas MR, Sanchez de Miguel L, Garcia-Duran M, González- Fernández F, Millás I, Montón M, et al. Expression of constitutive and inducible nitric oxide synthases in the vascular wall of young and aging rats. Circ Res 1998;83:279-86. (Pubitemid 28371317)
38. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, chalkley count, and computer image analysis. J Pathol 1995;177:275-83.
39. Weidner N. Measuring intratumoral microvessel density. Methods Enzymol 2008;444:305-23.
40. Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci U S A 1999;96:9944-8. (Pubitemid 29398837)
41. Sakaguchi Y, Shirahase H, Ichikawa A, Kanda M, Nozaki Y, Uehara Y. Effects of selective iNOS inhibition on type II collagen-induced arthritis in mice. Life Sci 2004;75:2257-67. (Pubitemid 39180035)
42. Cheng X, Pang CC. Increased vasoconstriction to noradrenaline by 1400W, inhibitor of iNOS, in rats with streptozotocin-induced diabetes. Eur J Pharmacol 2004;484:263-8. (Pubitemid 38117219)
43. Meyer RE, Shan S, DeAngelo J, Dodge RK, Bonaventura J, Ong ET, et al. Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br J Cancer 1995;71:1169-74.
44. Swaroop GR, Kelly PA, Bell HS, Shinoda J, Yamaguchi S, Whittle IR. The effects of chronic nitric oxide synthase suppression on glioma pathophysiology. Br J Neurosurg 2000;14:543-8. (Pubitemid 32055663)
45. Tozer GM, Prise VE, Lewis G, Xie S, Wilson I, Hill SA. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses. Clin Cancer Res 2009;15:3781-90.